Related Experiment Video
Updated: Jun 3, 2026

06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Accelerated T2 mapping for characterization of prostate cancer
Wei Liu1, Baris Turkbey, Julien Sénégas
1Philips Research North America, Briarcliff Manor, New York, USA. wei.liu2.ctr@us.army.mil
Magnetic Resonance in Medicine
|March 12, 2011
Summary
Accelerated prostate T(2) mapping accurately quantifies T(2) values, showing lower values in malignant tumors compared to normal tissues. This technique offers an effective approach for prostate cancer assessment.
Area of Science:
- Radiology
- Medical Imaging
- Magnetic Resonance Imaging
Background:
- Prostate cancer diagnosis relies on accurate imaging.
- T(2) mapping provides quantitative MRI information.
- Accelerated imaging techniques can improve scan efficiency.
Purpose of the Study:
- To evaluate an accelerated multiecho spin-echo sequence for prostate T(2) mapping.
- To assess the accuracy and reproducibility of the accelerated method.
- To determine if accelerated T(2) mapping can differentiate malignant prostate tumors.
Main Methods:
- Prostate T(2) mapping was performed in 34 patients using an accelerated sequence with 4-fold k-space undersampling (acceleration factor 3.3) on a 3T scanner.
- Accelerated and conventional sequences were compared for T(2) value correlation (r=0.99).
- Interscan reproducibility was assessed across prostate segments.
Main Results:
- High correlation (r=0.99) was observed between accelerated and conventional T(2) values.
- Good interscan reproducibility was demonstrated across prostate segments.
- Malignant tumors showed significantly lower T(2) values (100 ± 10 ms) than suspicious (114 ± 23 ms) and normal (149 ± 32 ms) tissues (p < 0.05).
Conclusions:
- Accelerated prostate T(2) mapping is accurate and reproducible.
- The technique effectively differentiates malignant prostate tumors based on T(2) values.
- This method offers an efficient approach for quantitative prostate MRI.

